Interne link ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 september 09, 2026 om 12:00 PM UTC
Interne link ProQR to Participate in Upcoming Investor Conferences in September 2026 september 02, 2026 om 12:00 PM UTC
Interne link ProQR Announces Second Quarter 2026 Operating and Financial Results augustus 13, 2026 om 11:00 AM UTC
Interne link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement juni 25, 2026 om 10:35 AM UTC
Interne link ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform juni 25, 2026 om 10:25 AM UTC
Interne link ProQR Announces First Quarter 2026 Operating and Financial Results mei 12, 2026 om 11:00 AM UTC
Interne link ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform mei 11, 2026 om 12:00 PM UTC
Interne link ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 mei 04, 2026 om 12:00 PM UTC
Interne link ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors april 30, 2026 om 12:00 PM UTC
Interne link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event april 08, 2026 om 08:00 PM UTC
Interne link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board april 08, 2026 om 12:00 PM UTC
Interne link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 maart 25, 2026 om 12:00 PM UTC
Interne link ProQR Announces Year End 2025 Operating and Financial Results maart 12, 2026 om 11:00 AM UTC
Interne link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference maart 03, 2026 om 09:30 PM UTC
Interne link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook januari 08, 2026 om 01:00 PM UTC
Interne link ProQR Announces Extraordinary General Meeting of Shareholders december 27, 2017 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa november 29, 2017 om 12:00 PM UTC
Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference november 21, 2017 om 12:00 PM UTC
Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares november 14, 2017 om 12:44 PM UTC
Interne link ProQR Announces Proposed Public Offering of Ordinary Shares november 13, 2017 om 09:01 PM UTC
Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness november 13, 2017 om 12:00 PM UTC
Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board november 09, 2017 om 12:00 PM UTC